GLP1R and type 2 diabetes mellitus: Liraglutide (LIRA) is a therapeutic option for the treatment of glycemic alterations and/or type 2 diabetes mellitus (DM2) (1,2), acting as an agonist of glucagon-like peptide 2 (GLP-1) receptors (1).